How Actemra is Administered for Rheumatoid Arthritis
Actemra (tocilizumab) treats moderate to severe rheumatoid arthritis (RA) in adults who haven't responded well to TNF antagonists. It's given as either intravenous (IV) infusions or subcutaneous (SC) injections, with dosing based on body weight, response, and treatment history.[1]
IV Infusion Dosing and Schedule
For IV use, patients receive 4 mg/kg every 4 weeks, which can increase to 8 mg/kg if needed. Infusions last 1 hour in a clinical setting, typically every 4 weeks. This route suits those starting treatment or preferring monitored administration.[1][2]
Subcutaneous Injection Option
SC Actemra uses pre-filled syringes or autoinjectors: 162 mg weekly for patients under 100 kg, or every other week for those 100 kg or more. Patients or caregivers self-administer after training, offering home convenience over clinic visits.[1][2]
Differences Between IV and Subcutaneous
IV provides higher initial doses for faster response but requires healthcare facilities. SC matches efficacy long-term with similar safety, ideal for maintenance. Switching between routes is possible without dose adjustment.[1][3]
How Long Until It Works and Monitoring
Effects often appear within weeks, but full RA symptom relief may take 3-6 months. Doctors monitor blood counts, liver function, and lipids before and during treatment due to infection and cholesterol risks.[1][2]
Common Patient Questions on Self-Injection
Store SC Actemra refrigerated; let it warm to room temperature before injecting into the thigh, abdomen, or upper arm. Rotate sites to avoid irritation. Training videos and resources are available from Genentech.[2]
[1]: Actemra Prescribing Information (Genentech)
[2]: Actemra HCP Site
[3]: Drugs.com - Actemra